An Innovative Approach to Navigating Patients Through Cancer Diagnostics

Precision Medicine Stewardship: A Model from Astera Cancer Care

When ACCC began its journey to explore how cancer programs and practices around the country are meeting the demands of increased precision medicine testing, the concept of precision medicine stewards—a nuanced approach to navigation that is focused exclusively on biomarker testing processes and results reporting—was fairly new. Yet the variety of models and titles that have emerged since continue to multiply and are breaking down the complex precision medicine landscape into streamlined workflows to improve efficiency and better support growing test volumes.

One such model is currently in place at Astera Cancer Care in New Jersey, where it has developed a unique approach by creating a centralized Molecular Processing department and team of dedicated staff to support the multiple aspects associated with molecular tests orders and results. ACCC recently talked to Lauren Kiley, MSN, APN-BC, AOCNP, advanced practice provider and director of patient navigation, and Melissa Cruz-Tanner, LPN, OPN-CG, manager of patient navigation and molecular processing, at Astera Cancer Care to learn more about their precision medicine stewardship model.

Astera Cancer Care has eight medical oncology outpatient clinics, eight radiation oncology hospital-based locations, and two breast surgery centers located across New Jersey, and offers multidisciplinary cancer care through a team of medical and radiation oncologists, hematologists, breast surgeons, pharmacists, advanced practice providers (APPs), and navigation and social support staff. While centralizing its molecular testing processes was critically important to Astera Cancer Care with the increased testing volumes, it was too much for their existing navigation team to handle. In examining the extensive time spent by patient navigators on tracking molecular tests, associated administrative tasks, and follow-up, the team at Astera Cancer Care determined that they needed to reassign this important, albeit time-consuming, task.

As Kiley explained, “My focus as director was to remove that task [tracking of molecular tests] from navigators and have them focus on the navigation involved [with molecular testing], rather than the administrative follow-up, but ensure that the process was not being lost.

So we determined that because it does require knowledge on medical terminology and involves collaborating with pathology departments, we decided to hire a medical assistant who would function full time, remotely in the role of [molecular] order processing and follow-up tracking.

The case was presented, as such, to our leadership—that molecular test processing is taking away from our navigation process and is outside of their scope of practice. Leadership agreed, and we were able to develop a molecular task force.”

At Astera Cancer Care, the precision medicine stewardship’s responsibilities are essentially distributed between patient navigators and molecular processors. With clear distinctions and separate responsibilities, this tag-team ensures precision medicine processes are seamless and bottlenecks and other delays do not occur.

Meanwhile, molecular processors act as the primary point of contact throughout the precision medicine stewardship process and are responsible for orders processing. They
input all information into the order within the portal, generate requisition forms that are placed into the EHR (and sent out if it is for liquid biopsy), and maintain relationships and communications with each of the preferred laboratory vendors. Next, they handle one of the most critical aspects of the process—monitoring and tracking test results. Molecular processors, who receive regular updates from vendors, enter the EHR and provide status updates on specimens to providers every 72 hours. This enables providers to know exactly where in the process the test is and significantly improves efficiency and reduces turnaround time. Beyond this, molecular processors are also responsible for quality testing and evaluation.

As Cruz explained, “On a minimum of two times per day, we access the portal in real-time, and we manually upload all the results that are available. Sometimes, it will just be verbiage that is updated, but providers generally request an updated PDF file. Some facilities have an interface base where they are automatically incorporated in the EHR, but that is not always the case. We have some vendors that send over results via fax, but you run the risk where it is put in the wrong patient’s chart, it’s incomplete, or the whole thing did not go through. So we have found [that] it is more reliable for our staff to go into the portal and upload [the] results themselves.”

**Key Recommendations**

While the team at Astera Cancer Care are proud of their current model and have been successful in establishing the role of these molecular processors, in retrospect, they recommend building the case for multiple processors to meet test volumes during the initiation phase, rather than seek approvals one at a time. Another recommendation is to establish clear guidelines with vendors to place increased responsibility on vendors rather than the cancer program, such as providing a dedicated liaison for communicating results or issues with specimens and providing a weekly spreadsheet with updates.

To those around the country who are looking at implementing a similar model, Astera Cancer Care gives this advice: *Be patient, because it’s going to be an uphill battle but definitely remain steadfast*. Make sure that you establish the most important objective—to decrease the time between the results and the patient receiving treatment—which is overall the most effective form of patient care. That, and ensuring that you capture measurements, activities, and [key performance indicators], anything that can document the volume of patients that are going to be significantly positively impacted by this new role, then that’ll be more likely for it to be accepted by the organization,” Cruz said.

For more information on the ACCC Precision Medicine Stewardship education program, visit accc-cancer.org/precision-medicine-stewardship.

**Acknowledgements**

ACCC wishes to thank the molecular processing team at Astera Cancer Care for their contributions to this article:

Lauren Kiley, MSN, APN-BC, AOCNP, Advanced Practice Provider and Director of Patient Navigation
Melissa Cruz-Tanner, LPN, OPN-CG, Manager of Patient Navigation and Molecular Processing

Association of Community Cancer Centers

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 30,000 multidisciplinary practitioners from 2,000 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org. Follow us on social media; read our blog, ACCCBuzz; tune in to our CANCER BUZZ podcast; and view our CANCER BUZZ TV channel.

© 2023. Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.

This publication is a benefit of ACCC membership

In partnership with:

AstraZeneca | bluePrint Medicines

The Precision Medicine Stewardship education program is supported by: